Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/b7/5e/0e/b75e0e66-d1e5-b31e-6eb2-cd134a385649/mza_18369675551325857977.jpg/600x600bb.jpg
Drug Target Review Podcast
Drug Target Review
41 episodes
1 week ago
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.
Show more...
Science
RSS
All content for Drug Target Review Podcast is the property of Drug Target Review and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.
Show more...
Science
https://i1.sndcdn.com/artworks-88PQJs3BXGyzjupG-rcjsyA-t3000x3000.jpg
Episode 23 - Making organoids ready for screening
Drug Target Review Podcast
33 minutes 35 seconds
2 years ago
Episode 23 - Making organoids ready for screening
In this episode titled: Making organoids ready for screening, sponsored by Revvity, we are understanding why researchers are turning to 3D Organoids and how organoids can be made ready for screening. This conversation features Dr Nathan Gödde, Manager of the Australian Organoid Facility at The University of Queensland and Dr Amee George, Manager of the ANU Centre of Therapeutic Discovery at the Australian National University.
Drug Target Review Podcast
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.